Does RCKT have chance to beat they're earnings?

Rocket (RCKT) has a positive chance of beating its earnings, but it's not a certainty. Here's a detailed analysis:

1. **Current Estimate**: The estimated EPS for RCKT in Q2 2025 is -$0.57, with an estimated revenue of $10.14 million.

2. **Historical Performance**: Rocket Pharmaceuticals has a history of earnings beats. In Q1 2025, the company reported an EPS of -$0.56, which topped the consensus estimate of -$0.58 by $0.02. This indicates that the company has the potential to exceed expectations.
3. **Market Sentiment**: Despite the positive sentiment, there are some concerns that could impact RCKT's performance. The FDA clinical hold on the RP-A501 trial has led to a significant stock price plunge and a class-action lawsuit. These factors could negatively affect investor confidence and, consequently, earnings.
4. **Quantitative Recommendation Score**: Rocket (RCKT) has a quantitative recommendation score of 0.14, which is relatively low compared to some other stocks. This suggests that while there is potential for a positive earnings report, it may not be the most compelling buy among the listed stocks.

|code|Ticker|Name|Date|Volume Ratio|market_code|
|---|---|---|---|---|---|
|LEGN|LEGN.O|Legend Biotech|20240717|1.2157|185|
|CSTL|CSTL.O|Castle Biosciences|20240717|1.3891|185|
|VERA|VERA.O|Vera Therapeutics|20240717|1.0024|185|
|VKTX|VKTX.O|Viking Therapeutics|20240717|2.2942|186|
|KYTX|KYTX.O|Kyverna|20240717|0.822|185|
|ARWR|ARWR.O|Arrowhead Pharmaceuticals|20240717|1.2071|185|
|RCKT|RCKT.O|Rocket|20240717|1.3156|185|
|LEGN|LEGN.O|Legend Biotech|20240718|0.5822|185|
|CSTL|CSTL.O|Castle Biosciences|20240718|0.7842|185|
|VERA|VERA.O|Vera Therapeutics|20240718|0.7844|185|

In conclusion, while Rocket (RCKT) has a chance of beating its earnings, it's important to consider the potential risks and market conditions. Investors should closely monitor the company's performance and any updates regarding the FDA clinical hold on the RP-A501 trial.